Viewing Study NCT05844202


Ignite Creation Date: 2025-12-25 @ 3:39 AM
Ignite Modification Date: 2025-12-26 @ 2:23 AM
Study NCT ID: NCT05844202
Status: COMPLETED
Last Update Posted: 2023-05-06
First Post: 2023-05-02
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Safety, Tolerability and Immunogenicity of Alveavax-v1.2, a BA.2/Omicron-optimized, DNA Vaccine for COVID-19 Prevention
Sponsor: Alvea Holdings, LLC
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module Annotation Module